ARTICLE | Emerging Company Profile
Frazier, Marcadia founders reunite for rare endocrine diseases in MBX’s $34.6M A round
MBX is applying peptide optimization tech from an Indiana University lab to rare endocrine disorders
July 28, 2020 2:25 AM UTC
Kent Hawryluk and Richard DiMarchi are following up on the first two companies they formed together, diabetes-focused Marcadia and MB2, with rare endocrine diseases play MBX Biosciences.
Frazier, which led Marcadia Biotech Inc.’s series A round, also led MBX Biosciences Inc.’s $34.6 million series A. Other participants in the Indiana-based company’s financing, which includes an initial $2.5 million financing in September, included OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund, Indiana Seed Fund III and Twilight Venture Partners II...